Cover Image
市場調查報告書

Shire Plc - 產品平台分析

Shire Plc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224555
出版日期 內容資訊 英文 145 Pages
訂單完成後即時交付
價格
Back to Top
Shire Plc - 產品平台分析 Shire Plc - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 145 Pages
簡介

Shire Plc是高度專業性的生物製藥公司,致力於藥劑產品的研究、開發及商品化。同時也提供注意力不足過動症(ADHD)和遺傳基因療法,腸胃障礙,再生醫療,其他的治療領域等廣幅治療藥。

本報告提供Shire Plc 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Shire Plc 基本資料

Shire Plc 概要

  • 主要資訊
  • 企業資料

Shire Plc :R&D概要

  • 主要的治療範圍

Shire Plc :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Shire Plc :開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Shire Plc :開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Shire Plc :藥物簡介

  • anagrelide hydrochloride
  • guanfacine hydrochloride ER
  • icatibant acetate
  • velaglucerase alfa
  • C1 esterase inhibitor (human)
  • hydrocortisone MR
  • lifitegrast
  • lisdexamfetamine dimesylate
  • prucalopride succinate
  • SHP-465
  • idursulfase
  • mecasermin rinfabate
  • LUM-001
  • maribavir
  • SHP-610
  • SHP-613
  • SSP-002358
  • VP-20621
  • PVS-10200
  • SHP-611
  • LUM-002
  • SHP-622
  • HGT-3010
  • SC-435
  • Small Molecule to Inhibit A2A Receptor for CNS Disorders
  • Antisense Oligonucleotide For Rare Genetic Disorders
  • etiguanfacine

Shire Plc :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Shire Plc :最近的開發平台趨勢

Shire Plc :暫停中的計劃

Shire Plc :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • NRP-290
    • SPD-452
    • SPD-453
    • SPD-756
    • anagrelide hydrochloride
    • CX-516
    • HCV-796
    • HGT-1111
    • HGT-2610
    • lisdexamfetamine dimesylate
    • mesalamine ER
    • metoclopramide hydrochloride
    • ramatercept
    • SHP-557
    • SPD-427
    • SPD-491
    • SPD-554
    • SPD-556
    • valrocemide

Shire Plc :企業發表

Shire Plc :總公司和子公司的所地

Shire Plc :主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07995CDB

Summary

Global Markets Direct's, 'Shire Plc - Product Pipeline Review - 2016', provides an overview of the Shire Plc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shire Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Shire Plc
  • The report provides overview of Shire Plc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shire Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shire Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Shire Plc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shire Plc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shire Plc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Shire Plc Snapshot
    • Shire Plc Overview
    • Key Information
    • Key Facts
  • Shire Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Shire Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Shire Plc - Pipeline Products Glance
    • Shire Plc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Shire Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shire Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Shire Plc - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Shire Plc - Drug Profiles
    • guanfacine hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lifitegrast
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • parathyroid hormone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • agalsidase alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • icatibant acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lanadelumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lisdexamfetamine dimesylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prucalopride succinate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-465
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teduglutide (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idursulfase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • maribavir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mecasermin rinfabate (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revexepride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-610
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-625
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-635
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-640
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VP-20621
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-611
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-622
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-623
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-627
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • volixibat potassium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Rare Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DX-2507
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DX-4012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate GTP Cyclohydrolase I for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HTL-1071
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Genetic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SC-435
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-630
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-637
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-639
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-641
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etiguanfacine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shire Plc - Pipeline Analysis
    • Shire Plc - Pipeline Products by Target
    • Shire Plc - Pipeline Products by Route of Administration
    • Shire Plc - Pipeline Products by Molecule Type
    • Shire Plc - Pipeline Products by Mechanism of Action
  • Shire Plc - Recent Pipeline Updates
  • Shire Plc - Dormant Projects
  • Shire Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • NRP-290
      • SPD-452
      • SPD-453
      • SPD-756
      • ALX-0646
      • BMN-185
      • C1 esterase inhibitor (human)
      • CX-516
      • ecallantide
      • HCV-796
      • HGT-1111
      • HGT-2610
      • icatibant acetate
      • isovaleramide
      • lisdexamfetamine dimesylate
      • mesalamine ER
      • metoclopramide hydrochloride
      • ramatercept
      • SHP-557
      • SHP-613
      • SHP-628
      • SPD-491
      • SPD-554
      • SPD-556
      • valrocemide
  • Shire Plc - Company Statement
  • Shire Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Shire Plc - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shire Plc, Key Information
  • Shire Plc, Key Facts
  • Shire Plc - Pipeline by Indication, 2016
  • Shire Plc - Pipeline by Stage of Development, 2016
  • Shire Plc - Monotherapy Products in Pipeline, 2016
  • Shire Plc - Partnered Products in Pipeline, 2016
  • Shire Plc - Partnered Products/ Combination Treatment Modalities, 2016
  • Shire Plc - Out-Licensed Products in Pipeline, 2016
  • Shire Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Shire Plc - Pre-Registration, 2016
  • Shire Plc - Phase III, 2016
  • Shire Plc - Phase II, 2016
  • Shire Plc - Phase I, 2016
  • Shire Plc - Preclinical, 2016
  • Shire Plc - Unknown, 2016
  • Shire Plc - Pipeline by Target, 2016
  • Shire Plc - Pipeline by Route of Administration, 2016
  • Shire Plc - Pipeline by Molecule Type, 2016
  • Shire Plc - Pipeline Products by Mechanism of Action, 2016
  • Shire Plc - Recent Pipeline Updates, 2016
  • Shire Plc - Dormant Developmental Projects,2016
  • Shire Plc - Discontinued Pipeline Products, 2016
  • Shire Plc, Other Locations
  • Shire Plc, Subsidiaries
  • Shire Plc, Key Manufacturing Facilities

List of Figures

  • Shire Plc - Pipeline by Top 10 Indication, 2016
  • Shire Plc - Pipeline by Stage of Development, 2016
  • Shire Plc - Monotherapy Products in Pipeline, 2016
  • Shire Plc - Partnered Products in Pipeline, 2016
  • Shire Plc - Out-Licensed Products in Pipeline, 2016
  • Shire Plc - Pipeline by Top 10 Target, 2016
  • Shire Plc - Pipeline by Route of Administration, 2016
  • Shire Plc - Pipeline by Top 10 Molecule Type, 2016
  • Shire Plc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top